BCDA BioCardia, Inc.
1.090USD+2.83%Mkt Cap: 16.50M $P/E: —1d ago
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is Car…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 BioCardia (BCDA) Q2 2026 Earnings Call Transcript Japan regulatory progress and narrowed losses drive CardiAMP advancement. | ||
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... BioCardia advances toward Japanese Shonin submission and FDA approval pathways while managing cash runway into 2027. | ||
 BioCardia, Inc. Q2 2026 Earnings Call Summary Moby summary of BioCardia, Inc.'s Q2 2026 earnings call | ||
 New Strong Sell Stocks for July 14th AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026. | ||